@Article{or.2022.027549,
AUTHOR = {SUCHITRA NISHAL, VIKAS JHAWAT, SUMEET GUPTA, PARMITA PHAUGAT},
TITLE = {Utilization of kinase inhibitors as novel therapeutic drug targets: A review},
JOURNAL = {Oncology Research},
VOLUME = {30},
YEAR = {2022},
NUMBER = {5},
PAGES = {221--230},
URL = {http://www.techscience.com/or/v30n5/51414},
ISSN = {1555-3906},
ABSTRACT = {Kinase inhibitors are a significant and continuously developing division of target therapeutics. The drug
discovery and improvement efforts have examined numerous attempts to target the signaling pathway of kinases. The
Kinase inhibitors have been heralded as a game-changer in cancer treatment. For developing kinase inhibitors as a
treatment for various non-malignant disorders like auto-immune diseases, is currently undergoing extensive research.
It may be beneficial to investigate whether cell-specific kinase inhibitor administration enhances therapeutic efficacy
and decreases adverse effects. The goal of the current review is to gain insight into the role of kinase inhibitors in
facilitating effective target drug delivery for the treatment of various anti-inflammatory, auto-immune, and anticancer
disorders. The aim of this review is also to shed light on drug discovery approaches for kinase inhibitors, their mode
of action, and delivery approaches. The variation in the binding of kinases bestows different target approaches in drug
design, which can be employed for designing the targeted molecules. Several target sites have been studied, exceeding
the design of drugs for various diseases like cancer, Alzheimer’s, rheumatoid arthritis, etc. Diverse delivery approaches
have also been studied for the targeted application of kinase inhibitors.},
DOI = {10.32604/or.2022.027549}
}